Who is sponsoring NCT00625157?

NCT00625157 is sponsored by Astion Pharma A/S.

What condition does NCT00625157 study?

NCT00625157 studies Discoid Lupus Erythematosus.

What drugs are being tested in NCT00625157?

Interventions: ASF 1096 0.5 % cream, ASF 1096 placebo cream.

What is the status of NCT00625157?

NCT00625157 is currently COMPLETED.

Last reviewed 2008-02-28 · How we verify

Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Patients With Newly Developed Discoid Lupus Erythematosus (DLE) Lesions. An International Multi-Centre Clinical Phase 2, Placebo Controlled and Double Blind Proof of Concept Study (2)

NCT00625157 Phase 2 COMPLETED

Lupus Erythematosus (LE) is an autoimmune disorder that includes a broad spectrum of clinical forms. One of these forms, Discoid Lupus Erythematosus (DLE) is a chronic disfiguring disease confined to the skin. The aim of this pivotal trial is to investigate the efficacy and safety of ASF-1096 cream 0.5% in the treatment of patients with DLE or SLE presenting newly developed discoid lesions.

Details

Lead sponsor	Astion Pharma A/S
Phase	Phase 2
Status	COMPLETED

Conditions

Discoid Lupus Erythematosus

Interventions

ASF 1096 0.5 % cream
ASF 1096 placebo cream

Countries

Denmark